1. Breast cancer in BRCA mutation carriers: medical treatment.

    Minerva ginecologica 68(5):557 (2016) PMID 26799758

    About 10% of breast cancers are associated with the inheritance of autosomal dominant breast cancer susceptibility alleles BRCA1 and BRCA2. Until recently, the medical management of BRCA mutation-associated breast cancer has not differed from that of the sporadic breast cancer counterpart. Howev...
  2. Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer.

    Cancer Treatment Reviews 48:1 (2016) PMID 27262016

    Omission of axillary dissection in women with breast cancer and one or two positive sentinel-node biopsy is a major advancement in the management of this disease. Supported by a sound rationale and confirmed by prospective, randomized trials, omission of axillary dissection is now recommended in...
  3. Changing paradigms in the treatment of hormone-receptor positive advanced breast cancer.

    Expert Opinion on Pharmacotherapy 17(8):1039 (2016) PMID 27042879

  4. "Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

    Oncotarget 7(14):17932 (2016) PMID 26910921 PMCID PMC4951261

    We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of HRs in HER2 positive BC, we retrospectively ident...
  5. Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.

    JAMA Oncology 2(4):445 (2016) PMID 26720497

    Patient perspective on chemotherapy-related adverse effects is being increasingly acknowledged both in experimental clinical trials and in clinical practice. To evaluate a 10-item, paper questionnaire derived from the US National Cancer Institute's Common Terminology Criteria for Adverse Events ...
  6. Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

    Journal of Cancer Research and Clinical Oncology 142(3):669 (2016) PMID 26531187

    Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared ...
  7. AKT signaling in ERBB2-amplified breast cancer.

    Pharmacology & Therapeutics 158:63 (2016) PMID 26645663 PMCID PMC4747800

    The PI3K/AKT pathway is the focus of several targeted therapeutic agents for a variety of malignancies. In ERBB2-amplified breast cancer, the hyperactivation of this signaling cascade is associated with resistance to ERBB2-targeted therapy. This can occur through gain-of-function alterations or ...
  8. p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.

    Oncotarget 7(4):4442 (2016) PMID 26716506 PMCID PMC4826217

    Overexpression of the ErbB2/HER2 receptor tyrosine kinase occurs in up to 20% of human breast cancers and correlates with aggressive disease. Several efficacious targeted therapies, including antibodies and kinase inhibitors, have been developed but the occurring of resistance to these agents is...
  9. Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.

    Expert Opinion on Investigational Drugs 25(4):393 (2016) PMID 26863927

    ErbB2 overexpression and/or gene amplification is present in 20% of all breast cancers and characterizes an aggressive form of this disease. Despite the availability of several active drugs that have yielded substantial survival improvements, most patients with ErbB2-positive metastatic disease ...
  10. Eribulin in pretreated metastatic breast cancer patients: results of the TROTTER trial-a multicenter retrospective study of eribulin in real life.

    SpringerPlus 5:59 (2016) PMID 26835238 PMCID PMC4720621

    This retrospective multicenter analysis was aimed to evaluate clinical activity and tolerability of eribulin in pretreated metastatic breast cancer patients in clinical practice. Patients treated with eribulin from January 2012 to July 2013 were enrolled in the observational study from 10 italia...
  11. Endocrine therapy in premenopausal women with breast cancer: a critical appraisal of current evidence.

    Expert Review of Anticancer Therapy 16(2):211 (2016) PMID 26634955

    Nearly 60% of all breast cancer premenopausal women are diagnosed with a hormone receptor positive tumor and, therefore, are candidates for adjuvant hormonal therapy. Treatment with tamoxifen for at least 5 years has been for a long time the standard of care, as it is associated with overall pos...
  12. Predictive Factors of Lapatinib and Capecitabine Activity in Patients with HER2-Positive, Trastuzumab-Resistant Metastatic Breast Cancer: Results from the Italian Retrospective Multicenter HERLAPAC Study.

    PLoS ONE 11(5):e0156221 (2016) PMID 27224517 PMCID PMC4880338

    There are no validated predictive markers for lapatinib and capecitabine in patients with trastuzumab-resistant HER2 positive metastatic breast cancer. Data of 148 consecutive patients treated with lapatinib and capecitabine from March 2007 to December 2013 were collected from 13 Italian institu...
  13. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.

    Oncologist 20(8):880 (2015) PMID 26099741 PMCID PMC4524761

    We evaluated the patterns of care and clinical outcomes of metastatic breast cancer patients treated with first-line trastuzumab-based therapy after previous (neo)adjuvant trastuzumab. A total of 416 consecutive, HER2-positive metastatic breast cancer patients who had received first-line trastuz...
  14. Linifanib: current status and future potential in cancer therapy.

    Expert Review of Anticancer Therapy 15(6):677 (2015) PMID 25936222

    Angiogenesis is one of the major mechanisms controlling tumor proliferation and metastatic spreading. Targeting of pro-angiogenic factors and their downstream effectors represents an appealing therapeutic option in the treatment of different cancer types. Linifanib (ABT-869) is a novel tyrosine-...
  15. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

    The Lancet 385(9980):1863 (2015) PMID 25740286

    Whether addition of fluorouracil to epirubicin, cyclophosphamide, and paclitaxel (EC-P) is favourable in adjuvant treatment of patients with node-positive breast cancer is controversial, as is the benefit of increased density of dosing. We aimed to address these questions in terms of improvement...
  16. Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer.

    Cell Reports 11(4):564 (2015) PMID 25892239

    Understanding the molecular pathways that contribute to the aggressive behavior of HER2-positive breast cancers may aid in the development of novel therapeutic interventions. Here, we show that CDCP1 and HER2 are frequently co-overexpressed in metastatic breast tumors and associated with poor pa...
  17. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

    New England Journal of Medicine 372(17):1672 (2015) PMID 25901437

    To the Editor: The results of the Suppression of Ovarian Function Trial (SOFT) by Francis et al. (Jan. 29 issue)1 are presented as practice changing. However, we are concerned about the emphasis given to the receipt of adjuvant chemotherapy — which was considered as a proxy for a disea...
  18. Adjuvant ovarian suppression in premenopausal breast cancer.

    New England Journal of Medicine 372(17):1672 (2015) PMID 25901438

  19. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.

    Expert Opinion on Investigational Drugs 24(3):421 (2015) PMID 25645727

    Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathwa...
  20. By promoting cell differentiation, miR-100 sensitizes basal-like breast cancer stem cells to hormonal therapy.

    Oncotarget 6(4):2315 (2015) PMID 25537513 PMCID PMC4385854

    Basal-like breast cancer is an aggressive tumor subtype with a poor response to conventional therapies. Tumor formation and relapse are sustained by a cell subset of Breast Cancer Stem Cells (BrCSCs). Here we show that miR-100 inhibits maintenance and expansion of BrCSCs in basal-like cancer thr...